Soluble complement receptor type 1 (CD35) in bronchoalveolar lavage of inflammatory lung diseases.
Complement receptor type 1 (CR1) (CD35; C3b/C4b receptor) is a transmembrane protein of many haematopoietic cells. Once cleaved, soluble complement receptor type 1 (sCR1) exerts opposite effects as a powerful inhibitor of complement. This study addressed both the question of whether sCR1 was found in bronchoalveolar lavage (BAL) of normals and patients with various inflammatory disease, and its possible origin. In this retrospective study covering specimen and clinical data of 124 patients with acute and chronic inflammatory lung pathologies, BAL supernatants were analysed by enzyme-linked immunosorbent assay technique for sCR1. Correlations were made between the sCR1 levels obtained and the constituents of BAL. Human alveolar macrophages were cultivated in order to determine their secretory capacity of sCR1. Alveolar macrophages from normal subjects were shown to release sCR1 in vitro. In addition, sCR1 was present in BAL of normal controls and was significantly increased in acute inflammatory lung diseases such as acute respiratory distress syndrome (ARDS), bacterial and Pneumocystis carinii pneumonia, as well as in chronic inflammatory diseases such as interstitial lung fibrosis and sarcoidosis. In BAL of ARDS, bacterial, and P. carinii pneumonia, there was a good correlation between sCR1 and the absolute neutrophil counts. In sarcoidosis, a correlation was found with BAL lymphocyte counts. Serum sCR1 was not increased in patients compared to controls. Soluble complement receptor type 1 (sCR1) is found in the bronchoalveolar lavage in health as well as in acute and chronic inflammatory disease. Alveolar macrophages are capable of releasing sCR1 in vitro and may be the main physiological source of sCR1 in the alveoli. The good correlation between sCR1 and the absolute neutrophil or lymphocyte numbers in bronchoalveolar lavage of inflammatory diseases suggests a predominant role of leucocytes for the release of sCR1 in such conditions. The release of this inhibitor of complement may be crucial to control and reduce complement activation and thus prevent lung injury.
Hamacher
J
J
Pulmonary Division, Hôpital Cantonal Universitaire, Geneva, Switzerland.
Sadallah
S
S
Schifferli
J A
JA
Villard
J
J
Nicod
L P
LP
D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology*; D002470:Cell Survival / Q000502:physiology; D004355:Drug Stability; D006801:Humans; D019272:Leukocyte Elastase / Q000032:analysis; D008171:Lung Diseases / Q000378:metabolism; D016676:Macrophages, Alveolar / Q000276:immunology / Q000502:physiology; D009504:Neutrophils / Q000201:enzymology; D011014:Pneumonia / Q000276:immunology*; D017463:Receptors, Complement 3b / Q000032:analysis* / Q000737:chemistry; D012016:Reference Values; D012995:Solubility
D017463:Receptors, Complement 3b; D019272:Leukocyte Elastase